Quanterix Inc - QTRX Net earnings per share for the last 12 months

Quanterix Corporation (QTRX) develops unique Simoa systems that enable the diagnosis of brain pathologies long before standard tests. Market price action reflects an EPS (TTM) of -1.30. The business relies on external sensor supplies while maintaining full internal control over assembly. Growing interest from neurologists and biopharma companies in blood biomarker discovery is driving a rapid surge in equipment orders.
Quanterix - analytical breakdowns and key metrics (QTRX)

Stable demand for neurodegenerative disease diagnostics minimizes the impact of R&D budget cyclicality on the Quanterix Corporation (QTRX) business. Year-over-year EPS (TTM) growth reflects this resilience, measuring the percentage change in net income per share over a rolling year. This metric allows for the elimination of quarterly volatility, capturing the real efficiency of capital generation. By analyzing the historical annual dynamics of EPS TTM, an investor can objectively assess the fundamental strength of the company.